Request a Consultation Are you looking to enhance your fat metabolism, boost your energy levels, and support your liver function
Conditions Treated with Trigger Point Injections Trigger point injections are highly effective for: Myofascial pain syndrome Chronic tension headaches Fibromyalgia Neck and back pain Postural strain from prolonged desk work Sports-related muscle injuries What to Expect During and After the Injection During the procedure: Youll be asked to sit or lie in a comfortable position
Too many operations simply took the old diet package established in the late 50s and still use it today without bearing in mind the changes in food processing, our body evolution, and current lifestyles
References Journal of Endocrinology & Metabolism (2014) Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health Journal of Clinical Endocrinology & Metabolism (PubMed) Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults European Journal of Endocrinology (PubMed) Ipamorelin: the first selective growth hormone secretagogue Translational Andrology and Urology (PMC) Role of growth hormone secretagogues in body composition management Endocrinology (OUP) hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights CDC Preventing unsafe injection practices: multi-dose vial handling guidelines Journal of Endocrinology & Metabolism (2013) Safety and tolerability of the hexadecapeptide AOD9604 in humans Obesity Pharmacotherapy Review (PMC) AOD-9604 clinical trial overview and weight loss outcomes Subcutaneous Drug Injection Review (PMC) Pharmacologic considerations of the subcutaneous route CDC Vaccine administration: subcutaneous route (angle/site guidance) MedlinePlus Subcutaneous injections: patient instructions and technique NCBI Bookshelf Best practices for injection: asepsis, preparation, and administration Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
Normal circulating IGF-I and GHBP are fully restored only after experimental intra-peritoneal (70) or intraportal (71) insulin delivery
doi: 10.1016/S0304-3940(02)01164-3 15
